Study Details
Testing the Drug NEU-411 for Companion Diagnostic-Positive People with Early Parkinsons Disease
(IRB#: IRB_00188883)
Parkinsons Disease affects the central nervous system of the body, causing issues of movement such as shaking, slowness, balance problems, and difficulty thinking. NEU-411 is a study drug to treat people with this disease. This study wants to see if the drug will help people with the disease and is safe. People in the study will be randomly chosen to be treated with NEU-411 or a placebo. The placebo looks like the study product but does not have the medication. Being in the study requires about 19 in-person visits at the clinic over 67 weeks. Medical tests will be done during the study to track the health of participants.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 50 to 80 years old
- Diagnosis of Parkinsons Disease
- At least 6 months of Parkinsons Disease cardinal symptoms
- Able to use a smartphone and an application to measure Parkinsons Disease symptoms
- Able to attend in-person visits at the study clinic
Exclusion Criteria
- Live in a nursing home
- Unable to stop using specific medications
- Uncontrolled diabetes
- Major surgery within 3 months of participation or planned during study
- Severe medical condition that prevents full study participation
Will I be paid for my time?
Yes
IRB#: IRB_00188883
PI: Paolo Moretti
Department: NEUROLOGY
Approval Date: 2025-08-06 06:00:00
Study Categories: Brain Health Studies
Specialties: Neurology
I am Interested